These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 32080309

  • 1. 68Ga-labeled PSMA-11 (68Ga-isoPROtrace-11) synthesized with ready to use kit: normal biodistribution and uptake characteristics of tumour lesions.
    Kurash MM, Gill R, Khairulin M, Harbosh H, Keidar Z.
    Sci Rep; 2020 Feb 20; 10(1):3109. PubMed ID: 32080309
    [Abstract] [Full Text] [Related]

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.
    Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.
    Hell J Nucl Med; 2019 Feb 20; 22(1):6-9. PubMed ID: 30843003
    [Abstract] [Full Text] [Related]

  • 3. Biodistribution of [(68)Ga]PSMA-HBED-CC in Patients with Prostate Cancer: Characterization of Uptake in Normal Organs and Tumour Lesions.
    Prasad V, Steffen IG, Diederichs G, Makowski MR, Wust P, Brenner W.
    Mol Imaging Biol; 2016 Jun 20; 18(3):428-36. PubMed ID: 27038316
    [Abstract] [Full Text] [Related]

  • 4. Normal distribution pattern and physiological variants of 68Ga-PSMA-11 PET/CT imaging.
    Demirci E, Sahin OE, Ocak M, Akovali B, Nematyazar J, Kabasakal L.
    Nucl Med Commun; 2016 Nov 20; 37(11):1169-79. PubMed ID: 27333090
    [Abstract] [Full Text] [Related]

  • 5. Primary lymph-node staging with 68Ga-PSMA PET in high-risk prostate cancer: pathologic correlation with extended pelvic lymphadenectomy specimens.
    Corona-Montes VE, González-Cuenca E, Fernández-Noyola G, Olarte-Casas MA, Bobadilla-Salazar D, Medrano-Urtecho HM, Asimakopoulos AD.
    Urol Oncol; 2021 Aug 20; 39(8):494.e1-494.e6. PubMed ID: 33223371
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Impact of uptake time on image quality of [68 Ga]Ga-PSMA-11 PET/CT.
    van der Sar ECA, Viol SLM, Braat AJAT, van Rooij R, Lam MGEH, de Jong HWAM, de Keizer B.
    Med Phys; 2023 Dec 20; 50(12):7619-7628. PubMed ID: 37093883
    [Abstract] [Full Text] [Related]

  • 9. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions.
    Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, Holland-Letz T, Giesel FL, Kratochwil C, Haufe S, Haberkorn U, Zechmann CM.
    Eur J Nucl Med Mol Imaging; 2013 Apr 20; 40(4):486-95. PubMed ID: 23179945
    [Abstract] [Full Text] [Related]

  • 10. Cold Kit for Prostate-Specific Membrane Antigen (PSMA) PET Imaging: Phase 1 Study of 68Ga-Tris(Hydroxypyridinone)-PSMA PET/CT in Patients with Prostate Cancer.
    Hofman MS, Eu P, Jackson P, Hong E, Binns D, Iravani A, Murphy D, Mitchell C, Siva S, Hicks RJ, Young JD, Blower PJ, Mullen GE.
    J Nucl Med; 2018 Apr 20; 59(4):625-631. PubMed ID: 28986512
    [Abstract] [Full Text] [Related]

  • 11. Diagnostic value of dual-time point 68Ga-PSMA PET/CT image for benign and malignant lesions in patients with prostate cancer.
    Xiao L, Su M, Li Y.
    Abdom Radiol (NY); 2024 Sep 20; 49(9):3214-3219. PubMed ID: 38546825
    [Abstract] [Full Text] [Related]

  • 12. Correlation of Lesional Uptake Parameters and Ratios with miPSMA Score and Estimating Normal Physiologic Concentration: An Exploratory Analysis in Metastatic Castration-Resistant Prostatic Carcinoma Patients with 68Ga-PSMA-11 PET/CT.
    Kalshetty A, Menon B, Rakshit S, Bhattacharjee A, Basu S.
    J Nucl Med Technol; 2021 Sep 20; 49(3):235-240. PubMed ID: 34244223
    [Abstract] [Full Text] [Related]

  • 13. 68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour.
    Uprimny C, Kroiss AS, Decristoforo C, Fritz J, von Guggenberg E, Kendler D, Scarpa L, di Santo G, Roig LG, Maffey-Steffan J, Horninger W, Virgolini IJ.
    Eur J Nucl Med Mol Imaging; 2017 Jun 20; 44(6):941-949. PubMed ID: 28138747
    [Abstract] [Full Text] [Related]

  • 14. Distribution of prostate cancer recurrences on gallium-68 prostate-specific membrane antigen (68 Ga-PSMA) positron-emission/computed tomography after radical prostatectomy with pathological node-positive extended lymph node dissection.
    Huits TH, Luiting HB, van der Poel HG, Nandurkar R, Donswijk M, Schaake E, Vogel W, Roobol MJ, Wit E, Stricker P, Emmett L, van Leeuwen PJ.
    BJU Int; 2020 Jun 20; 125(6):876-883. PubMed ID: 32181951
    [Abstract] [Full Text] [Related]

  • 15. Early Injection of Furosemide Increases Detection Rate of Local Recurrence in Prostate Cancer Patients with Biochemical Recurrence Referred for 68Ga-PSMA-11 PET/CT.
    Uprimny C, Bayerschmidt S, Kroiss AS, Fritz J, Nilica B, Svirydenka H, Decristoforo C, von Guggenberg E, Horninger W, Virgolini IJ.
    J Nucl Med; 2021 Nov 20; 62(11):1550-1557. PubMed ID: 33712533
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of early imaging with 68Ga-PSMA-I&T in the discrimination of pelvic lesions in prostate cancer patients.
    Özülker F.
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019 Nov 20; 38(2):100-105. PubMed ID: 30514659
    [Abstract] [Full Text] [Related]

  • 17. Physiological biodistribution on Ga68-PSMA PET/CT and the factors effecting biodistribution.
    Arçay Öztürk A, Erkılıç M, Bural GG, Aydın F, Boz A.
    Ann Nucl Med; 2024 Nov 20; 38(11):894-903. PubMed ID: 38980577
    [Abstract] [Full Text] [Related]

  • 18. Pilot Comparison of ⁶⁸Ga-RM2 PET and ⁶⁸Ga-PSMA-11 PET in Patients with Biochemically Recurrent Prostate Cancer.
    Minamimoto R, Hancock S, Schneider B, Chin FT, Jamali M, Loening A, Vasanawala S, Gambhir SS, Iagaru A.
    J Nucl Med; 2016 Apr 20; 57(4):557-62. PubMed ID: 26659347
    [Abstract] [Full Text] [Related]

  • 19. 68Ga-PSMA PET/CT and Volumetric Morphology of PET-Positive Lymph Nodes Stratified by Tumor Differentiation of Prostate Cancer.
    Vinsensia M, Chyoke PL, Hadaschik B, Holland-Letz T, Moltz J, Kopka K, Rauscher I, Mier W, Schwaiger M, Haberkorn U, Mauer T, Kratochwil C, Eiber M, Giesel FL.
    J Nucl Med; 2017 Dec 20; 58(12):1949-1955. PubMed ID: 28637799
    [Abstract] [Full Text] [Related]

  • 20. High negative predictive value of 68Ga PSMA PET-CT for local lymph node metastases in high risk primary prostate cancer with histopathological correlation.
    Rahman LA, Rutagengwa D, Lin P, Lin M, Yap J, Lai K, Mancuso P, Rathore P, Haghighi K, Gassner P, Wong LH, Lalak N.
    Cancer Imaging; 2019 Dec 11; 19(1):86. PubMed ID: 31829288
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.